Literature DB >> 15570415

A triage strategy based on clinical risk factors for selecting elderly women for treatment or bone densitometry: the EPIDOS prospective study.

P Dargent-Molina1, S Piault, G Bréart.   

Abstract

A triage strategy, based on a clinical hip fracture risk score, may be used to classify elderly women into three groups: one at high risk and requiring treatment, another needing further assessment by bone densitometry, and a third at low risk. We used prospective data from the EPIDOS study (7512 women older than 75 years and followed for an average of 3.9 years) to assess the potential value of such a strategy for identifying elderly women with a hip fracture risk twice the cohort average (i.e. > or =20 per 1000 woman-years). An individual fracture risk score was calculated with the final risk function (Cox model). To compare this strategy with systematic BMD measurement and with current European recommendations, we examined the number of high-risk women identified, their average risk levels, sensitivity for hip fracture, and the number of high-risk women who need to be treated to prevent one hip fracture (hypotheses: all identified women are treated; sensitivity is equal to the point estimate; treatment reduces fracture risk by 35%). A triage strategy based on age, fracture history since the age of 40 years, body mass index, number of instrumental activities of daily living for which assistance is needed, grip strength, and visual acuity can identify 20% of the cohort as at high risk, 75% of them from clinical factors only, and the rest after BMD measurements (threshold: -2.5 T-score). The triage strategy would be significantly more sensitive than systematic BMD screening (51 versus 35%) and would require many fewer BMD examinations (10%). Compared with current recommendations, triage would identify fewer women (20 versus 28%) but at a significantly higher average risk of hip fracture (30 versus 20 per 1000 woman-years). Fewer high-risk women would be treated to prevent one hip fracture (29 versus 41) and fewer bone densitometry tests would be needed (10% versus 54%). The proposed triage strategy may be a useful clinical tool for selecting elderly women for treatment or bone densitometry.

Entities:  

Mesh:

Year:  2004        PMID: 15570415     DOI: 10.1007/s00198-004-1781-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  10 in total

1.  Effect and offset of effect of treatments for hip fracture on health outcomes.

Authors:  B Jonsson; J Kanis; A Dawson; A Oden; O Johnell
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

2.  A new approach to the development of assessment guidelines for osteoporosis.

Authors:  J A Kanis; D Black; C Cooper; P Dargent; B Dawson-Hughes; C De Laet; P Delmas; J Eisman; O Johnell; B Jonsson; L Melton; A Oden; S Papapoulos; H Pols; R Rizzoli; A Silman; A Tenenhouse
Journal:  Osteoporos Int       Date:  2002-07       Impact factor: 4.507

Review 3.  Identifying bone-mass-related risk factors for fracture to guide bone densitometry measurements: a systematic review of the literature.

Authors:  M Espallargues; L Sampietro-Colom; M D Estrada; M Solà; L del Rio; J Setoain; A Granados
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

4.  Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease.

Authors:  J A Kanis; P Delmas; P Burckhardt; C Cooper; D Torgerson
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

5.  Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Executive summary.

Authors: 
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

Review 6.  2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

Authors:  Jacques P Brown; Robert G Josse
Journal:  CMAJ       Date:  2002-11-12       Impact factor: 8.262

7.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Authors:  M R McClung; P Geusens; P D Miller; H Zippel; W G Bensen; C Roux; S Adami; I Fogelman; T Diamond; R Eastell; P J Meunier; J Y Reginster
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

Review 8.  Treatment of postmenopausal osteoporosis.

Authors:  Pierre D Delmas
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

9.  Fall-related factors and risk of hip fracture: the EPIDOS prospective study.

Authors:  P Dargent-Molina; F Favier; H Grandjean; C Baudoin; A M Schott; E Hausherr; P J Meunier; G Bréart
Journal:  Lancet       Date:  1996-07-20       Impact factor: 79.321

10.  Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.

Authors:  D Marshall; O Johnell; H Wedel
Journal:  BMJ       Date:  1996-05-18
  10 in total
  4 in total

1.  Validation of the Cummings' risk score; how well does it identify women with high risk of hip fracture: the Tromsø Study.

Authors:  Luai A Ahmed; Henrik Schirmer; Vinjar Fønnebø; Ragnar M Joakimsen; Gro K Berntsen
Journal:  Eur J Epidemiol       Date:  2006-11-22       Impact factor: 8.082

2.  Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data.

Authors:  Joanne LaFleur; Carrie McAdam-Marx; Stephen S Alder; Xiaoming Sheng; Carl V Asche; Jonathan Nebeker; Diana I Brixner; Stuart L Silverman
Journal:  J Bone Miner Metab       Date:  2010-08-06       Impact factor: 2.626

3.  Development of a prediction tool for low bone mass based on clinical data and periapical radiography.

Authors:  R Licks; V Licks; F Ourique; H Radke Bittencourt; V Fontanella
Journal:  Dentomaxillofac Radiol       Date:  2010-05       Impact factor: 2.419

Review 4.  The 'Ossebo' intervention for the prevention of injurious falls in elderly women: background and design.

Authors:  Patricia Dargent-Molina; Fabienne El Khoury; Bernard Cassou
Journal:  Glob Health Promot       Date:  2013-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.